1. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D

2. 2008 FDA Guidance

3. First Antihyperglycemic Agent to Show a CV Benefit -- Empagliflozin

4. Data on Canagliflozin and Other SGLT2 Inhibitors

5. GLP-1 Receptor Agonists Have Also Shown CV Benefit

6. CVOT Data on Other GLP-1 Receptor Agonists

7. Upcoming CVOT Data

8. Common Adverse Events

9. Diabetes Drug Label Updates for Reduction of CVD Death

10. Clinical Application for Primary Care, Endocrinology, and Cardiology

11. Viewpoint From a Diabetologist/Endocrinologist

12. Viewpoint From a Cardiologist

13. How Endocrinology and Cardiology Can Work Together for Improved Patient Outcomes

14. Abbreviations